What new antibiotics target multidrug-resistant and carbapenem-resistant Gram-negative bacteria?

The recent agents include ceftolozane-tazobactam (C-T), ceftazidime-avibactam (CAZ-AVI), meropenem-vaborbactam (MER-VAB), delafloxacin (DFX), plazomicin (PLZ), eravacycline (ERV), imipenem-relebactam (I-R), cefiderocol (CFD), temocillin (TMC), and aztreonam-avibactam (ATM-AVI). Most were approved by the FDA or EMA between 2014 and 2019, with ATM-AVI still moving through approval.

How do beta-lactam and beta-lactamase inhibitor combinations fight resistance?

Inhibitors such as tazobactam, avibactam, vaborbactam, and relebactam protect the partner beta-lactam from serine beta-lactamases (Ambler classes A, C, and D). Avibactam, vaborbactam, and relebactam do not inhibit metallo-beta-lactamases (class B), which is the main gap these combinations leave open.

Which new antibiotic works against metallo-beta-lactamase (MBL) producers?

Aztreonam-avibactam (ATM-AVI) is the key option, because aztreonam naturally resists MBLs while avibactam inactivates the serine beta-lactamases that MBL-producing strains often co-express. Cefiderocol also stays active against many MBL-positive strains through its separate iron-transport entry route.

What is cefiderocol and how does it enter bacterial cells?

Cefiderocol (Fetroja) is a siderophore cephalosporin approved in 2019 for complicated urinary tract infections and hospital-acquired pneumonia. It binds bacterial iron-transport receptors and is actively carried across the Gram-negative outer membrane, which lets it bypass the porin barrier that blocks many other antibiotics.

What are the main resistance mechanisms that emerge against these new antibiotics?

The dominant mechanisms are loss or alteration of outer-membrane porins (OmpK35, OmpK36, OprD), overproduction of efflux pumps, mutations in beta-lactamase genes such as blaKPC, target modifications (PBPs, 16S rRNA methyltransferases, DNA gyrase/topoisomerase IV), and production of metallo-beta-lactamases or OXA-type enzymes that the inhibitors cannot block.

Does ceftazidime-avibactam work against all carbapenem-resistant bacteria?

No. Ceftazidime-avibactam is highly effective against KPC and many class A, C, and D serine beta-lactamases, but it does not inhibit metallo-beta-lactamases (MBLs) or OXA-type carbapenemases, and its activity drops when porins such as OmpK35 and OmpK36 are lost.

Why is antibiotic stewardship important for these new agents?

Resistance to each of these drugs can appear quickly through mutation, porin loss, pump overproduction, and horizontal gene transfer. Sustained effectiveness depends on using them only when indicated, combining them when the biology requires it, monitoring local resistance patterns, and supporting surveillance and new drug development.

What is plazomicin used for and what limits its activity?

Plazomicin is an aminoglycoside approved in 2018 for complicated urinary tract infections and pyelonephritis caused by carbapenem-resistant Enterobacterales, including KPC-producers. Its activity is limited by the AAC(2)-Ia enzyme, which acetylates the drug, and by 16S rRNA methyltransferases such as ArmA that alter the ribosomal target.

New Antibiotics for MDR and Carbapenem-Resistant Gram-Negative Bacteria: How They Work

More than 2.8 million drug-resistant infections are reported in the United States every year. Europe loses tens of thousands of people to them annually, and the standard forecast is grim: if nothing changes, antimicrobial resistance could kill around ten million people a year worldwide by 2050. The organism at the center of most of those hospital nightmares is the Gram-negative bacterium.

These bugs cause a large share of the infections people pick up in hospitals, nursing homes, and ICUs. The reason they’re so stubborn is structural. They wear an outer membrane that blocks most antibiotics from even getting in, and they carry enzymes and pumps that dismantle whatever does make it through. Once they also learn to shrug off carbapenems, the drugs we keep in reserve for the worst cases, the menu of options gets very short.

The past ten years have actually delivered a real batch of new antibiotics built for exactly this fight. Below I walk through the ones that matter, how each one kills the bacteria, and the resistance tricks that are already eroding them. If you prescribe these, study them, or just want to understand them, this is the picture as it stands now.

Why Gram-negative bacteria are so hard to treat

There are four main moves these bacteria use to defeat an antibiotic. They can tighten their outer membrane and porin channels so the drug never reaches its target. They can alter the bacterial protein the drug grabs onto, so it no longer fits. They can pump the drug straight back out of the cell. And most famously, they can chop the drug apart with enzymes called beta-lactamases.

Those beta-lactamases come in four classes, A through D. Classes A, C, and D work with a serine residue at their active site; class B are the metallo-beta-lactamases that need zinc. Carbapenem-resistant strains often make these enzymes, which is the whole reason carbapenems stop working. Keep that in mind, because every drug below is essentially a response to one of these defenses.

The new antibiotics, one by one

Ceftolozane-tazobactam (C-T)

The FDA approved this in 2014. It pairs a cephalosporin, ceftolozane, with tazobactam, which inhibits many class A and some class C beta-lactamases. Ceftolozane binds penicillin-binding proteins and shuts down cell wall synthesis. It covers E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and a few others.

Where it breaks down is AmpC overproduction, structural changes to narrow-spectrum OXA enzymes, and overactive efflux pumps. Strains that overproduce AmpC or carry OXA-2 and OXA-10 tend to lose susceptibility fast, and you can sometimes see cross-resistance pop up with ceftazidime-avibactam at the same time.

Ceftazidime-avibactam (CAZ-AVI)

Approved in 2015, this became the go-to option for carbapenem-resistant infections. Avibactam is not a beta-lactam at all. It forms a reversible bond with class A, C, and D serine beta-lactamases and shields ceftazidime from them. It works especially well against KPC-producers.

The limitation is blunt: avibactam does nothing against metallo-beta-lactamases, and resistance arrives through blaKPC mutations, loss of the OmpK35 and OmpK36 porins, and PBP mutations. Resistance runs higher in the non-fermenters than in Enterobacterales, which matches what we see in the clinic.

Meropenem-vaborbactam (MER-VAB)

This one reached the market in 2017. Vaborbactam protects meropenem from class A and C beta-lactamases, including KPC, which makes it a solid pick for KPC-producing Enterobacterales.

Resistance mostly shows up when the OmpK35 and OmpK36 porins disappear and when efflux pumps ramp up. Losing OmpK36 alone can raise the mutant prevention concentration many times over, and when you stack porin loss on top of pump overproduction, you get the highest resistance levels we measure.

Delafloxacin (DFX)

A fluoroquinolone approved in 2017, and an odd one because it’s anionic. It blocks DNA gyrase and topoisomerase IV, which stops DNA replication. Because it hits two targets, resistance usually needs several mutations in the QRDR region rather than just one.

Even so, target mutations in gyrA, parC, and parE plus overactive efflux pumps (MtrC-MtrD-MtrE, NorM) get there eventually. The practical warning is that strains already resistant to ciprofloxacin tend to be resistant to delafloxacin too.

Plazomicin (PLZ)

An aminoglycoside approved in 2018, plazomicin was designed to beat carbapenem-resistant Enterobacterales. It’s a derivative of sisomicin with chemical tweaks that let it dodge almost all the aminoglycoside-modifying enzymes. It binds the 30S ribosomal subunit and halts protein synthesis.

It still has two soft spots. The AAC(2)-Ia enzyme acetylates the drug and drives resistance, and 16S rRNA methyltransferases such as ArmA alter the target. Outside those, it stays broadly useful against CRE and KPC-producers, and it tends to beat the other aminoglycosides against KPC strains.

Eravacycline (ERV)

Approved in 2018 as Xerava for complicated intra-abdominal infections, eravacycline is a fluorinated tetracycline. It binds the 30S subunit about ten times more tightly than the older tetracyclines and works at a quarter of the concentration.

Resistance comes mainly from efflux pumps, especially the adeB pump in Acinetobacter, and from ribosomal protection proteins. The reassuring part is that the usual tetracycline resistance genes (tetA, tetB, tetM) barely dent its activity.

Imipenem-relebactam (I-R)

This combination, approved in 2019 as Recarbrio, adds relebactam to imipenem. Relebactam is a strong inhibitor of class A and C beta-lactamases and pulls imipenem’s MIC down by factors of 2 to 128 against ESBL- and KPC-producers.

Resistance builds through OmpK36 disruption, rising blaKPC copy number, and AmpC overproduction paired with porin loss. The hard limit is the same as with avibactam: relebactam is useless against MBLs and OXA-type enzymes, which caps where the drug can reach.

Cefiderocol (CFD)

Approved in 2019 as Fetroja, cefiderocol is the trojan horse of the group. It’s a siderophore cephalosporin that hijacks the bacterial iron-transport system to cross the outer membrane, so it slips past the barrier that blocks everything else. It’s approved for complicated urinary tract infections and hospital-acquired pneumonia.

Because it enters by a different door, it often stays active against strains that have already beaten carbapenems, CAZ-AVI, C-T, MER-VAB, and I-R. Resistance still turns up through PBP-3 mutations, beta-lactamase production, and efflux pump overproduction.

Temocillin (TMC)

Not approved by the FDA, but authorized in Belgium and the UK. Temocillin is a beta-lactam that targets PBP5 and PBP6 and holds up against many AmpC and ESBL enzymes. It binds heavily to plasma protein, yet keeps its killing power against Enterobacterales.

Resistance climbs with overproduction of the AcrD efflux pump and mutations in the BaeSR system. Resistant rates run clearly higher in ESBL and AmpC producers than in wild-type strains, which is the expected pattern.

Aztreonam-avibactam (ATM-AVI)

Still working through approval, though the EMA has recommended it as Emblaveo. This pairing fills the gap the others leave open: metallo-beta-lactamase infections. Aztreonam resists MBLs, but the strains that make MBLs usually also make serine beta-lactamases that destroy aztreonam, so avibactam steps in to knock those out.

Resistance develops through porin changes (OmpK35, OmpK36, OmpK37), overproduction of the AcrAB-TolC efflux pump, and carbapenemase overproduction in porin-deficient backgrounds.

The real problem is resistance itself

Step back and the pattern across all ten is the same. Each drug was engineered to outsmart one specific resistance mechanism, and each is already being circled by the next one: porin loss, efflux pump overproduction, beta-lactamase mutations, target modifications. On top of that, bacteria swap genes horizontally, form biofilms, and make epigenetic changes to their targets. That spreading happens faster than we’d like.

So surveillance, new drug development, and disciplined stewardship aren’t three separate nice-to-haves. They’re the same effort seen from different angles. No single molecule is a permanent answer, and the response has to span microbiology, pharmacology, and public health at once, with countries actually talking to each other.

What this means if you prescribe or just want to understand the field

The toolkit against multidrug-resistant Gram-negative bacteria is genuinely better than it was a decade ago. But how long it stays useful depends entirely on using these drugs well: saving them for the infections that need them, combining them when the biology demands it, and watching local resistance patterns instead of guessing. Knowing both how a drug works and how bacteria defeat it isn’t a bonus anymore. It’s the baseline.